LY96 and type 2 diabetes mellitus: SIGLEC1 has been reported to negatively regulate the TLR-4-mediated inflammatory response [46], in keeping with the positive correlation between SIGLEC1 and TLR4:MD-2 complex in the control group; again, this relationship was not seen in the T2D group.